276 related articles for article (PubMed ID: 23499225)
1. Effectiveness and safety of daptomycin in complicated skin and soft-tissue infections and bacteraemia in clinical practice: results of a large non-interventional study.
Gonzalez-Ruiz A; Beiras-Fernandez A; Lehmkuhl H; Dohmen PM; Loeffler J; Chaves RL
Int J Antimicrob Agents; 2013 Apr; 41(4):372-8. PubMed ID: 23499225
[TBL] [Abstract][Full Text] [Related]
2. Daptomycin: the role of high-dose and combination therapy for Gram-positive infections.
Gould IM; Miró JM; Rybak MJ
Int J Antimicrob Agents; 2013 Sep; 42(3):202-10. PubMed ID: 23845504
[TBL] [Abstract][Full Text] [Related]
3. Safety and clinical outcomes when utilizing high-dose (> or =8 mg/kg) daptomycin therapy.
Moise PA; Hershberger E; Amodio-Groton MI; Lamp KC
Ann Pharmacother; 2009 Jul; 43(7):1211-9. PubMed ID: 19584384
[TBL] [Abstract][Full Text] [Related]
4. Management of cSSTIs: the role of daptomycin.
Garau J
Curr Med Res Opin; 2006 Nov; 22(11):2079-87. PubMed ID: 17076967
[TBL] [Abstract][Full Text] [Related]
5. Daptomycin versus other antimicrobial agents for the treatment of skin and soft tissue infections: a meta-analysis.
Bliziotis IA; Plessa E; Peppas G; Falagas ME
Ann Pharmacother; 2010 Jan; 44(1):97-106. PubMed ID: 19934396
[TBL] [Abstract][Full Text] [Related]
6. Daptomycin in the Clinical Setting: 8-Year Experience with Gram-positive Bacterial Infections from the EU-CORE(SM) Registry.
Gonzalez-Ruiz A; Gargalianos-Kakolyris P; Timerman A; Sarma J; José González Ramallo V; Bouylout K; Trostmann U; Pathan R; Hamed K
Adv Ther; 2015 Jun; 32(6):496-509. PubMed ID: 26108157
[TBL] [Abstract][Full Text] [Related]
7. [Daptomycin--a new antibiotic for the treatment of skin and soft tissue infections].
Mathiesen L; Midtvedt T; Solberg CO
Tidsskr Nor Laegeforen; 2006 Sep; 126(18):2383-4. PubMed ID: 16998552
[TBL] [Abstract][Full Text] [Related]
8. [Pharmacoeconomic assessment of daptomycin as first-line therapy for bacteraemia and complicated skin and skin structure infections caused by gram-positive pathogens in Spain].
Grau S; Rebollo P; Cuervo J; Gil-Parrado S
Rev Esp Quimioter; 2011 Sep; 24(3):154-63. PubMed ID: 21947099
[TBL] [Abstract][Full Text] [Related]
9. Daptomycin: a review of its use in the management of complicated skin and soft-tissue infections and Staphylococcus aureus bacteraemia.
Hair PI; Keam SJ
Drugs; 2007; 67(10):1483-512. PubMed ID: 17600394
[TBL] [Abstract][Full Text] [Related]
10. Daptomycin: first in a new class of antibiotics for complicated skin and soft-tissue infections.
Kern WV
Int J Clin Pract; 2006 Mar; 60(3):370-8. PubMed ID: 16494659
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of Effectiveness and Safety of High-Dose Daptomycin: Results from Patients Included in the European Cubicin(®) Outcomes Registry and Experience.
Seaton RA; Menichetti F; Dalekos G; Beiras-Fernandez A; Nacinovich F; Pathan R; Hamed K
Adv Ther; 2015 Dec; 32(12):1192-205. PubMed ID: 26610384
[TBL] [Abstract][Full Text] [Related]
12. Daptomycin: rationale and role in the management of skin and soft tissue infections.
Seaton RA
J Antimicrob Chemother; 2008 Nov; 62 Suppl 3():iii15-23. PubMed ID: 18829721
[TBL] [Abstract][Full Text] [Related]
13. Postmarketing clinical experience in patients with skin and skin-structure infections treated with daptomycin.
Owens RC; Lamp KC; Friedrich LV; Russo R
Am J Med; 2007 Oct; 120(10 Suppl 1):S6-12. PubMed ID: 17904950
[TBL] [Abstract][Full Text] [Related]
14. Real-world daptomycin use across wide geographical regions: results from a pooled analysis of CORE and EU-CORE.
Seaton RA; Gonzalez-Ruiz A; Cleveland KO; Couch KA; Pathan R; Hamed K
Ann Clin Microbiol Antimicrob; 2016 Mar; 15():18. PubMed ID: 26976128
[TBL] [Abstract][Full Text] [Related]
15. Daptomycin for outpatient parenteral antibiotic therapy: a European registry experience.
Seaton RA; Gonzalez-Ramallo VJ; Prisco V; Marcano-Lozada M; Gonzalez-Ruiz A; Gallegos B; Menichetti F; Loeffler J; Bouylout K; Chaves RL
Int J Antimicrob Agents; 2013 May; 41(5):468-72. PubMed ID: 23473943
[TBL] [Abstract][Full Text] [Related]
16. Safety and efficacy of daptomycin as first-line treatment for complicated skin and soft tissue infections in elderly patients: an open-label, multicentre, randomized phase IIIb trial.
Konychev A; Heep M; Moritz RK; Kreuter A; Shulutko A; Fierlbeck G; Bouylout K; Pathan R; Trostmann U; Chaves RL
Drugs Aging; 2013 Oct; 30(10):829-36. PubMed ID: 23990341
[TBL] [Abstract][Full Text] [Related]
17. Current management of patients hospitalized with complicated skin and soft tissue infections across Europe (2010-2011): assessment of clinical practice patterns and real-life effectiveness of antibiotics from the REACH study.
Garau J; Ostermann H; Medina J; Avila M; McBride K; Blasi F;
Clin Microbiol Infect; 2013 Sep; 19(9):E377-85. PubMed ID: 23663184
[TBL] [Abstract][Full Text] [Related]
18. Retrospective case-control analysis of patients with staphylococcal infections receiving daptomycin or glycopeptide therapy.
Falcone M; Russo A; Pompeo ME; Vena A; Marruncheddu L; Ciccaglioni A; Grossi P; Mancini C; Novelli A; Stefani S; Venditti M
Int J Antimicrob Agents; 2012 Jan; 39(1):64-8. PubMed ID: 22047703
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and safety of daptomycin in Japanese pediatric participants with complicated skin and soft tissue infections or bacteremia caused by gram-positive cocci.
Iwata S; Koyama H; Murata Y
J Infect Chemother; 2022 Mar; 28(3):406-412. PubMed ID: 34920946
[TBL] [Abstract][Full Text] [Related]
20. Daptomycin for the treatment of surgical site infections.
Chamberlain RS; Culshaw DL; Donovan BJ; Lamp KC
Surgery; 2009 Aug; 146(2):316-24. PubMed ID: 19628091
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
